Compare FULC & HBCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FULC | HBCP |
|---|---|---|
| Founded | 2015 | 1908 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.8M | 533.9M |
| IPO Year | 2019 | 2008 |
| Metric | FULC | HBCP |
|---|---|---|
| Price | $3.64 | $66.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | $16.38 | ★ $65.50 |
| AVG Volume (30 Days) | ★ 4.2M | 54.7K |
| Earning Date | 04-27-2026 | 04-20-2026 |
| Dividend Yield | N/A | ★ 1.98% |
| EPS Growth | N/A | ★ 29.01 |
| EPS | N/A | ★ 1.45 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.97 |
| P/E Ratio | ★ N/A | $46.30 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.83 | $49.49 |
| 52 Week High | $15.74 | $68.65 |
| Indicator | FULC | HBCP |
|---|---|---|
| Relative Strength Index (RSI) | 32.75 | 55.44 |
| Support Level | $2.83 | $62.28 |
| Resistance Level | $8.18 | N/A |
| Average True Range (ATR) | 0.27 | 1.59 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 20.76 | 56.75 |
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities.It is holding company for Home Bank, N.A. The principal sources of funds are customer deposits, repayments of loans, repayments of investments, and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.